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INTRODUCTION
Doxorubicin (DOX) has been a staple chemotherapeutic agent for decades, treating adult
and childhood malignancies. It is one of the most common anti-cancer drugs used in
treating different types of cancers including: pediatric cancer, leukemia, breast cancer [1].
DOX’s anti-cancer effect is exerted through DNA intercalation and inhibition of the
topoisomerase II enzyme in fast-proliferating tumors [1]. DOX thus halts cancer
metastasis, and ultimately leads to cancer cell death. However, its use has become limited
due to its cardiotoxic effect. Specifically, DOX promotes cumulative dose-dependent
cardiotoxicity, which affects the heart’s functionality and can lead to irreversible damage
[2]. One of the underlying mechanisms of this adverse effect is the accumulation of
reactive oxygen species (ROS) in the mitochondria. Due to the nature of the
mitochondria-dense cardiac cells, doxorubicin-induced oxidative stress is up to 10 times
greater in the heart than in other tissues [3]. This leads to cardiac dysfunction and an
increased incidence of mortality due to developing cardiomyopathy.
Unfortunately, among cancer survivors, complications from cardiac-related
toxicity have become the second leading cause of death after secondary malignancy [4].
Specifically, cardiac events influenced by DOX are difficult to prevent when they can
occur within 2 to 3 days of treatment or 6 to 10 years after its last administration [5]. The
only FDA drug used in combination with DOX to prevent cardiotoxicity is dexrazoxane
(DEX) [6]. However, DEX also inhibits a form of the topoisomerase II enzyme which
may prevent DOX’s anti-cancer ability and promote the early development of secondary
malignancies in some cases [7]. Moreover, other drugs such as angiotensin inhibitors,
and β-blockers have also been attempted and though they have shown some protective
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action over Dox-induced cardiotoxicity they are not found to be highly successful in all
cases [8]. DOX has shown the most success with treating cancers, and an improved
method of drug delivery needs to be implemented so that patients can continue taking the
drug without subsequent risk of cardiotoxic effect.
Clinical manifestation of DOX-Induced Cardiotoxicity
Cardiotoxicity can have acute and chronic manifestations. In acute cardiotoxicity,
patients can develop arrhythmias, pericarditis-myocarditis syndrome, myocardial
infarction, sudden cardiac death, congestive heart failure (CHF), and cardiomyopathy.
Acute cardiotoxicity can occur within the first week of treatment for adults and children
and is usually reversible when DOX is discontinued. Chronic cardiotoxicity has two
subtypes: early-onset cardiotoxicity, which begins within a year of treatment, or lateonset chronic cardiotoxicity which can occur up to 30 years later. [9]. The risk of
experiencing cardiac-related events persists even after 45 years [4]. This range makes
preventing cardiotoxicity difficult.
Moreover, children and adult patients can show different cardiac pathological
changes. For both subcategories of chronic cardiotoxicity, children develop restrictive
cardiomyopathy, which can progress into dilated cardiomyopathy [10]. By contrast,
patients treated in adulthood develop dilated cardiomyopathy in both the early-onset and
late-onset progression of the cardiotoxicity [9]. In all manifestations of cardiotoxicity
patients demonstrate decreased contractility, leading to decreased systolic and diastolic
cardiac performance, leading to further complications, especially in children who often
require heart transplants as adults [9]. Once chronic progression of cardiotoxicity has
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developed, the damage is irreversible, and patients are subject to treatments that can only
help manage their symptoms. Therefore, preventing cardiotoxic effects is vital in
decreasing this irreversible damage.
One of the main risks in developing cardiotoxicity is reaching DOX cumulative
doses of 500 mg/m2 and above. In a study where 630 patients were followed while treated
with doxorubicin, all recruited patients demonstrated normal left ventricular ejection
fraction (LVEF) at the start of the study. By the end of the study, 149 experienced a
DOX-induced cardiac event defined as at least a 20% reduction in LVEF. The severity
and frequency of the cardiac events were closely related to the cumulative dose of DOX
given. Starting at a cumulative dose of 150 mg/m2 only 7% of patients experienced a
cardiac event, however that increased to “9%, 18%, 38%, and 65% of patients at
cumulative doses of 250 mg/m2, 350 mg/m2, 450 mg/ m2, and 550 mg/m2, respectively.”
[11]. A cumulative lifetime limit of 450 mg/m2 is recommended to reduce the likelihood
of developing cardiotoxicity. However, limiting DOX reduces patient options for
effective cancer treatments.
Molecular mechanisms of DOX-induced Cardiotoxicity
Several mechanisms have been suggested to explain why DOX-induced cardiotoxicity
occurs. One of the most widely accepted explanations for DOX’s cardiotoxicity is its
interactions with the mitochondria to promote the increase of ROS. If this effect is not
counteracted by antioxidants it can lead to mitophagy and cell death [12]. Apart from
this, DOX has also been linked to other mechanisms which include, altered iron
regulation, disrupted calcium homeostasis, autophagy, and the release of nitric oxide,
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inflammatory mediators, and apoptotic factors [1]. Our study focused on DOX
mitochondrial cardiotoxicity which ultimately contributes to cardiomyopathy.
DOX is a lipophilic cation that is attracted to the highly negative mitochondrial
membrane potential of -160 to -180 mV, compared to the cytoplasmic membrane
potential of -60 mV [13]. Thus, mitochondria become the subcellular target for DOXinduced toxicity. Mitochondria are membrane-bound organelles that generate energy, in
the form of ATP, to power the cell’s metabolic functions. To maintain the high cellular
demands of the heart, contractile cells (cardiomyocytes) require constant levels of ATP.
This explains why 30% of cardiomyocyte cells’ volume are solely comprised of
mitochondria, making the heart the most susceptible to DOX accumulation [14].
Once DOX enters the mitochondrial matrix and its tetracycline ring interacts with
the electron transport chain’s complex I. At this complex DOX gets reduced into its
reactive semiquinone free radical form. This compound then transfers an electron to
mitochondrial O2, generating superoxide anions (O2-). DOX repeats this process leading
to an accumulation of mitochondrial superoxide anions. Accumulation of these anions
lead to oxidative damage and mitochondrial dysfunction. Additionally, DOX further
contributes to mitochondrial dysfunction via calcium (Ca2+) upregulation, triggering the
opening of the mitochondrial permeability transition pores (mPTPs). This disrupts the
delicate electrochemical gradient that exists between the two membranes in the
mitochondrial. A depolarized mitochondrial membrane often leads to triggered
mitophagy and ultimately cell death. Finally, DOX has a high affinity for cardiolipin, a
phospholipid found on the cardiomyocyte’s mitochondria. It plays a vital role in
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regulating the electron transport chain and ATP levels. When DOX attaches it forms a
DOX-cardiolipin complex which inhibits complexes I and complex II thus inhibiting the
effectiveness of the pathway, also leading to mitochondrial dysregulation [15].
Mitochondrial function is vital for the health of cells as the cells. Increased mitochondrial
dysfunction along with decreased ATP levels significantly reduce cardiomyocytes’
ability to sustain normal contractility and once the damage is done the cardiotoxic effect
of DOX becomes irreversible [15].
Mitigation of Cardiotoxicity
There are currently no specific treatments available to mitigate DOX-induced
cardiomyopathy. In addition to limiting the cumulative dose, other methods have been
used in an attempt to minimize cardiotoxic risks. These methods include administering
DOX concurrently with other anti-tumor drugs, using DOX analogs, alternating drug
delivery, or using general antioxidants and iron chelators (i.e., DEX). However, the listed
approaches have shown limited success [8]. DEX is an iron chelator that works by
binding free iron which prevents the formation of a DOX-iron complex [16]. Binding of
iron to DOX promotes iron cycling between Fe3+ and Fe2+ and increases ROS [15].
However, DEX is the only iron chelator to show protection against DOX-induced
toxicity, suggesting an alternative mechanism for its protective effect [6]. Further
research found that DEX also inhibits DOX’s anti-cancer properties. Recall, DOX
inhibits topoisomerase II within the cell and mitochondria. DEX inhibits this pathway by
changing the configuration of topoisomerase II, preventing DOX from binding and
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inhibiting its ability to kill cancer cells [15]. This makes the use of DEX, to limit DOXinduced toxicity, inappropriate during cancer treatment.
Antioxidants
Antioxidants work well to reduce increased levels of ROS. Common antioxidants such as
vitamin A and C work to inhibit oxidants from reacting with each other. Yet, they do not
accumulate in the mitochondria where they are most needed. Fortunately, there are also
mitochondrial antioxidants, like mitoquinone (MitoQ), which are shown to be potentially
favorable in attenuating this DOX-induced increase in ROS [17]. Unlike vitamin A and
C, mitochondrial antioxidants accumulate in the mitochondria due to their positive charge
and lipophilic feature. Though MitoQ shows promising cardioprotective features, its
mechanisms have yet to be fully understood concerning its combined effect with DOX in
cardiac cells [14].
Due to Mitoquinone’s preference for accumulating in the mitochondria, this
TPP+-conjugated antioxidant is more potent in reducing intracellular ROS accumulation
than its lipophilic counterparts [18]. Similar to DOX, MitoQ also interacts with the
electron transport chain’s complex I, but instead of inhibiting the complex it has been
shown to have positive affect on the substrate levels surrounding this complex,
contrastingly to DOX, it improves oxidative phosphorylation at the mitochondrial level
[19]. This is an important characteristic to note because it can provide competitive
inhibition against DOX which is dependent on complex I for reduction. Additionally,
previous studies have also shown that MitoQ has also an ability toward reducing the
mitochondrial membrane potential [19]. The mitochondrial membrane potential is an
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important factor the cells depend on in order to sustain appropriate energy levels when
carrying out oxidative phosphorylation for ATP production. Many studies have
demonstrated that a dysregulation of this potential may be harmful and lead to increased
cell apoptosis but a reduction occurring in the presence of MitoQ does not show the same
cytotoxic effects [13, 19, 20]. DOX depends on the mitochondrial membrane potential to
accumulate within the mitochondria and if this potential is reduced then subsequent DOX
accumulation can be hypothesized to also demonstrate a reduction. MitoQ’s different
characteristics show great potential toward inhibiting DOX-induced damage on the
molecular level.
In order to understand the role MitoQ can play when given with DOX, first we
must understand what benefits it has when given on its own. For example, in a cell model
exploring the effect of Aβ peptides on N2a cells, incubation with MitoQ led to partial
protection against the effect of Aβ peptides which is known to lower cell viability and
contribute to mitochondrial dysfunction [18]. Similarly, in a mouse animal model, MitoQ
showed direct protection toward transgenic mice that overexpress human catalase
localized to the mitochondria (mCAT) against the effect of mitochondrial ROS
production [18]. These findings suggest that MitoQ could be beneficial for conditions and
diseases characterized by dysfunctional mitochondria [18]. MitoQ was also shown to be
effective in reducing ischemia-reperfusion injury when given for 8 weeks to hypertensive
rats, and this was associated with a reduction of systolic blood pressure and cardiac
hypertrophy [18]. These findings have led to further experimentation which explore
MitoQ’s benefits, safety, and efficacy.
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MitoQ is an approved dietary antioxidant supplement that is well tolerated when
given to healthy human adults and does not demonstrate significant adverse side effects
when given alone [21]. A recent study in 2018 was the first human trial to show that 6
weeks of daily oral supplementation with MitoQ suppressed mitochondrial-derived
oxidative stress and improved vascular endothelial function [22]. This is promising and
suggests that it might protect cardiac tissue against DOX-induced oxidative stress. Very
few studies have explored the effects of MitoQ as a protective agent against DOX
induced cardiotoxicity. The most related study is one where healthy rats were treated with
DOX, Mito-Q, and DOX plus Mito-Q (co-treatment) for 12 weeks [23]. The study found
that DOX alone decreased left ventricular function, attenuated cytochrome c-oxidase, and
altered healthy electron paramagnetic resonance in ex-vivo samples. All of these features
are associated with DOX-induced damage which leads to cardiac dysfunction. The cotreatment group however showed significant improvements to restore these
characteristics [23]. This study thus establishes the protective effect MitoQ has against
DOX-induced cardiotoxicity, yet the mechanisms are poorly understood. Alternate
methods of drug delivery such as MitoQ given as a pre-treatment have also not been
thoroughly explored.
Previous Studies
On our lab, has looked into the differences between MitoQ given as a pretreatment versus the benefits when given as a co-treatment with DOX. More specifically
we also explored to see if there were differences in benefit when MitoQ was given as a
pre-treatment 24 hours prior to DOX and compared that to the effects seen when given as
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co-treatment with DOX in H9c2 cells. It was observed that both pre-treatment and cotreatment with MitoQ significantly reduced DOX-induced toxicity measured by
intracellular dehydrogenase activity of viable cells and confirmed by calcein staining in
H9C2 myoblasts. However, higher efficacy in cellular protection was shown to be
significant when MitoQ was given as pre-treatment compared to MitoQ co-treatment
(Figure 1). Two different mechanisms have been proposed to explain these findings: (1)
accumulation of MitoQ in the mitochondria depends on mitochondrial membrane
potential, which competes with DOX and thus prevents its accumulation; (2) MitoQ and
DOX exert effects via the electron transport chain and cardiolipin, which may lead to
interference when given at the same time [13]. However, more studies need to be done to
fill this gap in understanding the mechanism behind the preferred pre-treatment potency.
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Finally, antioxidant enzymes play an essential role in modulating ROS and
reducing the damage done to cells via oxidative stress. Heme oxygenase-1 (HO-1) is an
antioxidant considered the main protein associated with diseases resulting from oxidative
and inflammatory insults [24]. First, heme oxygenase 1 is an inducible enzyme that
regulates mitochondrial quality control in the heart. Specifically, in regards to influencing
mitochondrial mechanisms, it has been shown to promote mitobiogenesis when
overexpressed in cardiomyocytes [25]. Hull et al.’s study found that overexpression of
heme oxygenase 1 prevented the increase of FIS-1, a protein expressed by dysfunctional
mitochondrial triggering cell apoptosis. This demonstrates that heme oxygenase 1 may
protect mitochondria by disrupting the positive feedback loop of mitochondrial injury and
oxidative stress leading to apoptosis [25].
Additionally, increased expression of HO-1 is closely associated with the
upregulation of superoxide dismutase 1 (SOD-1). Secondary antioxidant SOD-1
scavenges oxygen radicals that can be overproduced in the mitochondria’s electron
transport chain. It metabolizes superoxide radicals (O2-) to more stable molecules,
molecular oxygen (O2), and hydrogen peroxide (H2O2) [26]. In another study with
diabetic rats, upregulation of HO-1 led to a robust increase in extracellular superoxide
dismutase (EC-SOD) [27]. These proteins contributed to an increase in endothelial
relaxation and a decrease in superoxide anions. Considering that superoxide anions are
highly involved in the mitochondrial dysfunction associated with DOX-induced damage,
it would be interesting to determine whether induction of these enzymes contributes to
the protective effects of MitoQ. The goal of this project is to fill the gap regarding why
pre-treatment with MitoQ is more effective than co-treatment against DOX-induced H9c2
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cell damage. A better understanding of how pre-treatment with MitoQ protects cardiac
cells from the toxic effects of DOX might allow expansion of the clinical utility of this
chemotherapeutic agent.
Hypothesis, Aims, Expectations
Hypothesis
We hypothesized that pre-treating H9c2 cells with the mitochondrial antioxidant,
Mitoquinone, influences more mechanisms of protection against Doxorubicin-induced
cardiotoxicity as compared to when given as a co-treatment.
Specific Aim 1
We investigated several aspects of mitochondrial function, including the mitochondrial
membrane potential, oxidative stress using MitoSOX, and mitochondrial DOX
concentration via fluorescence measurements.
Specific Aim 2
We evaluated the expression of two important antioxidant enzymes: superoxide
dismutase and heme oxygenase within treatment groups of MitoQ alone, MitoQ given as
pre-treatment and co-treatment, and DOX alone.
Expectation
We expect the MitoQ pre-treatment to protect mitochondrial function by reducing DOX
intracellular accumulation and thus related DOX-induced oxidative stress in
cardiomyocytes. As seen in other cell types, MitoQ has been confirmed to show a
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decrease in ROS, and testing it on H9C2 cells shows much promise as an effect has been
demonstrated between a pre-treatment and co-treatment [13, 28]. We also expect an
increase in antioxidant enzyme expression for heme oxygenase 1 and superoxide
dismutase 1. These expectations will confirm mechanisms in which pre-treatment would
be most effective against DOX-induced cardiotoxicity.
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METHODS
H9C2 cells
Rat H9C2 cells, a clonal myoblast cell line derived from embryonic BD1X rat heart
tissue, were obtained from the American Type Culture Collection (ATCC, CRL-1446).
Cells were maintained in 75 cm2 flasks and petri dishes in high glucose Dulbecco’s
modified Eagle's medium (DMEM) (Corning Life Sciences, Presque, Pennsylvania,
USA), 1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA), and
10% fetal bovine serum (FBS) (Corning Life Sciences, Presque, Pennsylvania, USA).
The cultures were incubated at 37°C in 5% CO2 and medium. The medium was aspirated
every 2-3 days, and cells were washed twice with PBS. The process was repeated until
the cells reached 70%- 90% confluence for passaging. During passaging, cells were
detached using trypsin/EDTA (Sigma Aldrich, St Louis, MO, USA). After collection,
cells were resuspended in medium, and cells were counted using a 0.3% trypan blue kit
(Sigma-Aldrich, St. Louis, MO). Cells were plated at a density of 2 × 104 cells per well in
a 96-well plate. The remaining cell suspension was distributed into 150 mm cell culture
dishes with 10 mL of medium. Seeded plates were treated after a 24 hr. incubation
period, and dishes were treated once confluence reached 80%.
Experimental Groups
Doxorubicin or Mitoquinone alone
Cells in 96-well plates were treated with DOX alone (0.5–50 μM; M.W. =579.98g/mol,
Sigma-Aldrich, St. Louis, MO) or MitoQ alone (0.005µM-10µM; M.W. =678.8 g/mol,
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Cayman Chemical, Ann Arbor, Michigan). After cells were incubated for 24 hours,
biochemical assays were conducted.
Co-treatment or Pre-treatment with MitoQ and DOX
To establish the co-treatment condition, cells were concurrently treated with MitoQ
(0.005µM-10µM) and DOX (40µM). To establish the pre-treatment condition, H9c2 cells
were pre-treated with MitoQ alone (0.005uM-10 μM), incubated for 24 hours before
aspirating, and washed twice with PBS. After washing, the cells were given 100 µL of
new medium and treated with DOX (40 µM). Biochemical assays were then performed
after a 24 hr incubation period.
Biochemical Assays:
1. Cell Viability Analysis
Cell viability was evaluated using the Cell Counting Kit-8 (CCK), which is based on
intracellular dehydrogenase activity. Dehydrogenases reduce WST-8 cells to form
formazan which is directly proportional to the number of live cells. After completion of
treatments, cells were washed twice with PBS and supplemented with fresh medium.
Each well received 10 µL of CCK reagent and plates were incubated for 3-4 hours before
absorbance was measured at 450 nm using the iMark™ Microplate Absorbance Reader
(Bio-Rad)
2. Mitochondrial membrane potential (MMP) analysis
JC-10 (catalog #MAK159, SIGMA-ALDRICH) assay was used to observe differences in
mitochondrial membrane potential (Δψm). JC-10 is a cationic lipophilic dye that forms
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red-fluorescent JC-10 aggregates (λex = 540/λem = 590 nm) that concentrate in the
mitochondria of cells with polarized membranes. However, when the mitochondrial
membrane potential is depolarized, the mitochondria cannot retain the dye, and JC-10
changes into its monomeric form, emitting a green fluorescence (λex = 490/λem = 525
nm) as it diffuses out of the mitochondria. JC-10 stock solution was diluted in buffer A to
generate concentration of 1uM. Subsequently, the JC-10 or buffer A solution was added
to cells which had the same treatments, respectively, and then plates were incubated at 37
°C for 45 minutes. Upon completion of the incubation period, the imaging buffer B
solution was added to the cells. Fluorescence is measured by Fluoroskan Ascent CF
Microplate Reader (Catalog # 21748, Cambridge Scientific) at respective wavelengths
before adding JC-10 and after adding the buffer B solution. To remove interference of the
fluorescence produced by DOX, the difference between the same treatment wells with
JC-10 and without JC-10 were calculated. Lastly, the ratio between red fluorescence to
green fluorescence was used to indicate MMP.
Mitochondrial Superoxide Production:
MitoSOX™ Red mitochondrial superoxide indicator (Catalog # M36008, Thermo Fisher
Scientific) is a red fluorogenic dye used to visualize and measure the amount of
superoxide present within the mitochondria of living cells. Mitochondrial superoxide is a
byproduct that is generated during oxidative phosphorylation. Though usually a tightly
regulated system, the mitochondria’s electron transport chain allows for 1-3% leakage of
mitochondrial oxygen that is not fully reduced. They quickly react with electrons to form
superoxide anions, the predominant reactive oxygen species in the mitochondria. After
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treatments, cells were washed twice with PBS, and 100- µl culture medium was added to
each well with 100 µL of the 5 µM stock solution of MitoSOX. Cell plates were
protected from light by covering with aluminum foil and then incubated for 10 minutes at
37˚C. Fluorescence was read via a Fluoroskan Microplate Reader at (510 nm
excitation/590nm emission). MitoSOX fluorescence was first adjusted for DOX
fluorescence by subtracting a background fluorescence reading of DOX alone (λex =
510/λem = 590 nm) taken prior to the addition of MitoSOX. Then the value was adjusted
with viable cell number which was obtained from the CCK assay
Intracellular DOX measurement
After washing out all the drugs, a background fluorescence reading (λex = 510/λem =
590 nm) was taken from the cells which were treated with DOX alone or with MitoQ pretreatment or co-treatment. The difference between DOX treated and non-treated viable
cells indicated intracellular DOX accumulation.
Western blot
1.

Protein Collection

After cells in the dishes reached 80%-90% confluence, they were prepared for the
following conditions: non-treated control, MitoQ 2.5µM alone, DOX 40 µM alone, and
co-treatment or pre-treatment of MitoQ 2.5µM and DOX as described previously. After
cells were incubated for 24 hours, dishes were washed twice with PBS, and adherent cells
were mechanically removed via a scraper. Cells were pipetted with 1X PBS solution into
a 1.5 mL Eppendorf tube and centrifuged (5000rpm for 5 minutes at 4°C). The
supernatant was aspirated, and the cell pellet was lysed with 30 µL of lysis buffer
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containing Pierce RIPA Buffer (Catalog # UG286129, ThermoScientific), Halt Protease
Inhibitor (Catalog #WG322531, ThermoScientific), and EDTA Solution (Catalog
#WD323125, ThermoScientific). Upon completion of cell lysis, cells were centrifuged at
15000 rpm for 30 minutes for 4°C. The protein-rich supernatant was transferred to 0.5 ml
Eppendorf tubes, and the pellets containing lipids, and cellular and nuclear membranes
were discarded. Protein lysates were stored at -80 °C.
2.

Protein Quantification

Protein was quantified using the PierceTM BCA Protein Assay Kit. The Bovine Serum
Albumin (BSA) standard was diluted to various concentration levels from 0 to 2000
µg/mL. The samples and standards were added to a 96-well plate. Bradford Reagent was
used to dye the proteins, and absorbance was measured at 540 nm (Pierce BCA Protein
Assay Kit - Thermo Fisher Scientific, 2019). A standard curve of BSA concentration was
made to compare with collected samples, and levels of protein concentration were
determined.
3.

Gel Electrophoresis

Protein samples (25-50 µg) were mixed with a loading buffer (NuPAGE LDS Sample
Buffer 4X), then heated at 90-100 °C to denature the proteins and provide a negative
charge. Samples were loaded into a precast polyacrylamide gel (NuPAGE™ 10%, BisTris, 1.0 mm, Mini Protein Gels). The first well in the polyacrylamide gel was filled with
5 µL Bio-Rad Precision Plus Protein Dual-color Standards. After filling 1X NuPAGE
MOPS SDS Running Buffer into the Bio-Rad Vertical Electrophoresis Cell,
electrophoresis ran for one hour at a constant 150V.
4.

Gel Transfer and Imaging
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Proteins were transferred from the polyacrylamide gel to a nitrocellulose membrane using
the iBlot® Dry Blotting System. The membrane was first incubated by a 10x Blocking
buffer for 30 minutes before adding the primary antibody overnight at a dilution of
1:1000. The preparation for the primary antibodies were as follows: 1. For the B-actin
monoclonal antibody, blots were blocked with DI water and 5% milk for 30 minutes and
incubated in mouse anti-actin antibody, 1:1000, in DI Water/5% milk overnight at 4 °C,
2. For the monoclonal HO-1, blots were incubated in rabbit anti-HO-1 antibodies, 1:1000,
in DI Water/5% milk overnight at 4 °C, 3. For the monoclonal SOD-1, blots were
incubated in rabbit anti-SOD-1 antibody, 1:1000 in DI water/5% milk overnight at 4 °C.
After primary incubation, the membrane was rinsed with 10X FWBK Wash Buffer
(Catalog # 37577, ThermoScientific) at a 1:10 ratio with deionized water, then incubated
with the secondary antibody for 30 minutes at room temperature. B-actin blots were
incubated in antibody dilution solution with secondary anti-mouse, 1:1000. Both HO-1
and SOD-1 were incubated with anti-rabbit secondary, 1:1000, and antibody dilution
solution. Afterward, chemiluminescence reagents were used to visualize the bands with
the Bio-Rad ChemiDoc MP Imaging System (“iBlot ® Dry Blotting System Instructions
for using the iBlot ® Gel Transfer Device to perform dry blotting of proteins from minior midi-gels with iBlot ® Gel,” 2011). To prepare membranes for multiple probing, a
stripping buffer was used to remove previously bonded primary and secondary
antibodies. The membrane was then blocked for 30 minutes using 5% milk prior to reprobing.
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Statistics
All experiments were performed in triplicate and repeated at least three times. The data
was expressed by mean ± SE. The data were analyzed using ANOVA followed by the
Student Newman-Keuls Test. P-value of < 0.05 was considered statistically significant.
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RESULTS
DOX-induced cytotoxicity correlates with DOX intracellular accumulation
The effects of DOX (500 nm-50 μM, n = 3) on H9c2 cell viability is shown in Figure 2A
and demonstrate dose-dependent reductions. Compared to non-treated control cells,
treatment with DOX doses ranging from 40 μM to 50 μM significantly reduced cell
viability to 0.30 ± 0.17 and 0.21 ± 0.17 respectively (both p < 0.05, see Fig 2A).
Additionally, DOX demonstrated a dose-dependent increase in intracellular accumulation
(see Figure 2B). DOX 20 μM, 40 μM, and 50 μM demonstrated a significant increase in
DOX intracellular accumulation to 4.43 ± 0.65, 8.45 ± 1.94, 17.08 ± 3.20-fold when
compared to the non-treated control, respectively (n = 5, p < 0.05, see Fig 2B).

DOX increased mitochondrial superoxide levels and decreased MMP
We further explored the effect of DOX on the level of mitochondrial superoxide
anions and MMP (see Figure 3A-B). We found that DOX induced a dose-dependent
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increase in mitochondrial superoxide anions compared to the non-treated control. In
particular, the lower doses of DOX (5 μM and 10 μM) both significantly increased
mitochondrial superoxide levels to 1.37 ± 0.08 and 0.09-fold (n=3, p < 0.05 vs. control).
Additionally, the higher doses of DOX (20 μM, 40 μM, and 50 μM) also significantly
increased mitochondrial superoxide levels to 2.04 ± 0.11, 3.30 ± 0.17, and 5.45 ± 0.12fold, when compared to non-treated control, respectively (n = 3, p < 0.0001). This
showed a dose-dependent increase of DOX intracellular accumulation. Moreover, DOX
also reduced the MMP. The reduction reached a plateau at 1 μM, and higher doses of
DOX (5 μM – 50 μM) showed a significant reduction of the MMP to 16-18% of the nontreated control (n=3, p<0.05; see Fig 3B).

MitoQ’s effects on cell viability, mitochondrial superoxide levels, and MMP
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The effects of MitoQ (0.005 μM – 10 μM, n = 3) on H9c2 cell viability are shown in
Figure 4A. MitoQ alone slightly increased cell viability, but the effects were insignificant
compared to the non-treated control. Furthermore, MitoQ demonstrated a reduction in
mitochondrial superoxide anion levels in most doses (0.005 µM- 5 µM, see Fig 4B).
MitoQ (1 μM) showed the maximal reduction to 0.52 ± 0.01 when compared to nontreated control (n=4, p < 0.05; see Fig. 4B). By contrast, MitoQ (10 μM) significantly
increased superoxide levels to 1.38 ± 0.12, when compared to non-treated control (n=4, p
< 0.05, Fig. 4B).

Moreover, we explored MitoQ’s effect on the MMP shown in Figure 4C.
Compared to non-treated control, lower doses of MitoQ (0.005 -0.1 µM) maintained a
similar MMP as non-treated control. However, intermediate and higher doses of DOX
(1-10 µM) significantly reduced the MMP to 0.11- 0.15 when compared to non-treated
control (n=3, p<0.05; see Fig 4C).
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Co-treatment and Pre-treatment decreased intracellular DOX accumulation
We explored the effects of co-treatment and pre-treatment on the level of intracellular
DOX accumulation. Compared to DOX 40 µM, MitoQ (0.005-5 µM), co-treatment
showed a significant reduction in intracellular DOX accumulation in a dose-dependent
manner (see Fig 5A). MitoQ (2.5 μM) exhibited the maximal reduction of intracellular
DOX to 0.44 ± 0.10 when compared to DOX 40 μM (n=3, p<0.05). By contrast, MitoQ
(10 μM) significantly increased intracellular DOX accumulation to 1.59 ± 0.25 when
compared to DOX 40 μM (p < 0.05). Similarly, MitoQ, when given as pre-treatment, also
demonstrated a dose-dependent reduction in intracellular DOX accumulation compared
to the positive control (DOX 40 μM, see Fig 5A). MitoQ (0.05 μM) started to show a
significant reduction, which was 10 times higher than the dose (0.005 μM) when given as
co-treatment. By contrast, pre-treating with MitoQ (2.5 μM) exhibited a maximal
reduction of intracellular DOX to 0.22 ± 0.08 compared to DOX 40 μM. The effect was
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lower than the maximal effect of MitoQ (2.5 μM) when given as co-treatment.
Additionally, the 10 μM dose of MitoQ pre-treatment did not significantly reduce
intracellular DOX levels (n=3, 0.84 ± 0.25) relative to DOX 40 μM. However, DOX
levels were significantly lower than the effects of 10 μM MitoQ as co-treatment (p <
0.05, see Fig 5A).

Pre-treatment reduced mitochondrial superoxide levels
The effect of co-treatment and pre-treatment on mitochondrial superoxide levels is
illustrated in Figure 5B. We found that MitoQ as a co-treatment (n = 4) slightly reduced
mitochondrial superoxide levels, although the effects were insignificant compared to
DOX 40 μM (see Fig 5B). On the other hand, MitoQ as pre-treatment showed biphasic
effects on DOX-induced mitochondrial superoxide levels. At the lower doses of MitoQ
(0.005 μM and 0.1 μM), treated cells demonstrated a slight but significant increase (1.39
± 0.07 vs. control, n = 4, p < 0.05) in superoxide levels when comparing to DOX 40 μM
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and/or co-treatment at the same dose (n=4, p < 0.05). Contrastingly, all the higher doses
of MitoQ (1-10 μM) significantly reduced superoxide levels. MitoQ (2.5 μM) showed the
maximal reduction to 0.53 ± 0.07 when compared to DOX 40 μM (n = 4, p < 0.05).

Co-treatment and Pre-treatment reduced MMP
The effects of MitoQ co-treatment and pre-treatment on mitochondrial membrane
potential are illustrated in Fig 5C. Compared to DOX 40 μM, both MitoQ co-treatment
and pre-treatment showed similar results on MMP. Cells treated with the lower doses of
MitoQ (0.005 -0.1 μM) and the highest dose (10 μM) exhibited similar MMP as DOX 40
μM. By contrast, the intermediate and higher doses (1-10 μM) reduced MMP as
compared to DOX 40 μM alone, but not to a significant level.
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Effects of MitoQ, DOX, MitoQ co-treatment, and pre-treatment on HO-1 and SOD-1

The representative western blot results of MitoQ, DOX, MitoQ co-treatment, and
pre-treatment on the expression of antioxidant enzymes HO-1 and SOD-1 are illustrated
in Figure 6. MitoQ showed similar expression of HO-1 and SOD-1 as the non-treated
control. By contrast, DOX 40uM showed lower expression of both antioxidant enzymes
when compared to the non-treated control. Additionally, MitoQ pre-treatment exhibited
increased expression of both antioxidant enzymes compared to co-treatment.
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DISCUSSION
Dox-Induced H9c2 cell damage
DOX, a class of anthracyclines, has been a widely prescribed anti-cancer treatment
against various types of solid tumors. However, its use is limited due to its cardiotoxic
effect. Our study showed that DOX (0.5-50 μM) dose-dependently reduced H9c2 cell
viability and increased mitochondrial superoxide anions after 24 hours of incubation. Our
findings are supported by a study by Zhang et al. and Upadhayay et al., demonstrating
DOX’s dose-dependent effects on cell damage and elevated ROS following treatment [2,
29]. More specifically, in Upadhayay’s study, H9c2 cells treated with DOX (5 μM)
showed a 50% reduction in H9c2 cell viability, which is similar to what we found [29].
Even though they seeded their wells with 1x105 cells, which differs from the 2x104 that
we used, our experiments are almost identical in that we measured the differences based
on cell density compared to the non-treated control.
Doxorubicin intracellularly accumulates in the cell, but more specifically, it
targets the mitochondria [23]. Considering cardiac cells are dense in mitochondria and
highly dependent on mitochondrial pathways for energy, mitochondrial dysfunction
becomes detrimental to the overall functionality of the heart [31]. This leads to an
increased risk of congestive heart failure and mortality. As a cation, doxorubicin is
attracted to the -150-180 mV mitochondrial membrane potential, and its lipophilic
features allow it to easily permeate the mitochondria via passive diffusion. More
specifically, doxorubicin can accumulate in the mitochondria 100 times more than in the
plasma, ~50-100uM compared to 0.5-1uM, respectively [23]. Additionally, when it is
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intravenously infused, the distribution half-life of the drug is 3-5 minutes while the
terminal half-life is 24-36 hrs, demonstrating that it takes the body much more time to
process the drug out of the system, leaving the cells more prone to injury when
accumulating within non-cancerous sites [31]. Our study demonstrated DOX dosedependently accumulated within the cells and showed the most significant accumulation
among the highest doses (20-50 μM). Our data is supported by Sardão et al.’s study,
which observed doxorubicin’s intracellular accumulation on H9c2 cells via
epifluorescence microscopy [32]. Even though they more specifically measured for
nuclear accumulation of doxorubicin, they also mentioned that they could not exclude
mitochondrial accumulation.
ROS is the main contributor toward DOX’S proposed mechanisms of action,
leading to DOX-induced damage. More correlated explicitly to the mitochondria, DOX
induces an increase in superoxide anions. Superoxide anion formation can be attributed to
several proposed mechanisms. For example, doxorubicin attaches to cardiolipin, an inner
mitochondrial membrane protein that plays a key role in modulating enzymes for the
energy-producing electron transport chain. The DOX-cardiolipin complex causes
inhibition of the ETC’s Complex I and II, disrupting the pathway and promoting ROS
production [15].
Additionally, DOX can interact directly with complex I. It is reduced to the
reactive semiquinone free radical, donating an electron to O 2, creating the superoxide
anion (O2-), thus increasing ROS levels. The semiquinone becomes oxidized back to its
original quinone state to repeat the cycle in what is referred to as redox cycling. In our
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study, DOX (5-50 μM) significantly and dose-dependently increased levels of superoxide
anions which is consistent with the previously explained mechanism.
In addition to increased levels of ROS, DOX causes the disruption of intracellular
Ca2+ accumulation, inhibition of TOP II-B and anti-apoptotic proteins, and induction of
pro-apoptotic pathways in cardiomyocytes [2]. All of these pathways can trigger intrinsic
apoptosis in cardiomyocytes, as demonstrated in our data. DOX 40 μM and 50 µM
showed the most significant reduction in cellular viability, measured by intracellular
dehydrogenase activity of viable cells and confirmed by calcein staining. This is in
agreement with what we observed in our lab’s previous studies [13].
As previously mentioned, DOX can disrupt Ca2+ homeostasis and contribute to
Ca2+ overload, triggering the mitochondrial permeability transition pore (mPTP) opening.
An important consequence of the opening of the mPTP is that it allows H+ ions to
disperse freely, thus depolarizing the membrane potential and leading to decreased
production of ATP [33]. Our study demonstrated that DOX (1-50 μM) significantly
reduced the mitochondrial membrane potential in a dose-dependent manner compared to
the non-treated control. Similarly, Upadhayay and company also observed DOX-induced
membrane potential depolarization in H9c2 cells. They looked further to see if the
depolarization affected cytochrome C levels. Due to the Ca2+ imbalance and the opening
of the mPTP, the mitochondria become more permeable to cytochrome-c, an important
indicator for cell apoptosis and necrosis [15, 29]. Using western blot to evaluate the
expression difference in H9c2 cells, Upadhayay’s found DOX treatment (5 μM)
upregulated cytochrome-C after 24 hours of incubation, thus resulting in an increased
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level of cellular death, also demonstrated by our observed effect with DOX on cell
viability. To summarize, our data showed that DOX exerted a dose-dependent increase in
mitochondrial superoxide anions and DOX intracellular accumulation, leading to lower
levels of cell viability with increasing doses.
MitoQ reduces mitochondrial superoxide levels and MMP
MitoQ is one of the most extensively studied mitochondrial antioxidants and is
now in phase II of human trials [34]. Currently, MitoQ is available over counter as an
anti-oxidant supplement. This study suggested that MitoQ alone did not significantly
reduce cell viability. Compared to non-treated control, it demonstrated a slight increase in
cell viability in the middle dose ranges (0.005 – 5 μM).
Mitoquinone is a ubiquinone derivative conjugated to triphenylphosphonium
(TPP) and lipophilic in nature. Unlike other ubiquinone analogs, it selectively
accumulates in the mitochondria several hundred folds more than in the cytoplasm [17,
35]. Within the mitochondria, MitoQ’s ubiquinone moiety is reduced to ubiquinol by
complex II, forming a potent antioxidant. In this form, it constantly gets recycled by
components of the ETC [35]. Our data showed that MitoQ significantly reduced
mitochondrial superoxide anion levels in most doses (0.005 µM- 5 µM). However,
MitoQ (10 μM) significantly increased superoxide levels when compared to non-treated
control. Fink et al’s study suggested that the pro-oxidant feature of MitoQ depends on
fuel selectively in vascular endothelial cells [19]. They let bovine aortic endothelial cells
exposed to differing concentrations of complex I substrates, and MitoQ was evaluated.
Results demonstrated that even though pro-oxidant effects were observed, alongside

34
decreased membrane potential, cytotoxic effects were not observed, which is similar to
what we with respective to non-significant changes made to cell viability. However,
further research is required to elucidate its safe dose range and potential toxicity.
MMP is not a direct indicator of cytotoxicity when comparing MitoQ to DOX
Our data indicated that MitoQ significantly reduced MMP. However, cell viability
was not impacted with reduced MMP after administration of MitoQ. This is a different
scenario when compared to DOX-induced cell damage. DOX not only reduced MMP but
also induced higher mitochondrial superoxide production. Both disturbances and other
proposed mechanisms (e.g., cardiolipin damage) determined cell death. It requires more
attention that higher doses of MitoQ can be cytotoxic [20, 36, 37]. Mendez et al. found
that MitoQ (10 μM) is cytotoxic to platelets [37]. Similarly, Ng MRAV, et al. report that
guinea pigs with co-treatment of MitoQ (20 mg/kg) and gentamycin (130 mg/kg) showed
severe multiple organ damage [20]. Therefore, the safe profile of MitoQ warrants further
evaluation.
MitoQ pre-treatment reduced intracellular DOX accumulation and mitochondrial
superoxide levels and upregulated antioxidant enzymes
In the clinical setting, heart pre-conditioning by transient ischemia/reperfusion episodes
is a strategy that helps the heart to develop resilience to harsher conditions such as a
prolonged reperfusion injury. This strategy attempts to mitigate DOX-induced
cardiotoxicity. Maulik et. al. demonstrated that preconditioning via
hypoxia/reoxygenation helped to attenuate the DOX-induced cardiotoxic effect against
cardiac myocytes [38]. Similarly, Galan-Arriola et al.’s study found that remote ischemic
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preconditioning before DOX treatment significantly preserved left ventricular ejection
fraction, mitochondrial morphology, and DNA copies in pigs’ hearts [39]. However, in
our study, using ischemic preconditioning, we pretreated cells with the mitochondrialtargeted antioxidant, MitoQ, 24 hours before DOX (40 μM) or concurrently with DOX.
We also compared the effects of pre-treatment to those of co-treatment.
Our previous study showed that both co-treatment and pre-treatment
demonstrated an increased level of cell viability when compared to DOX 40 uM.
However, co-treatment and pre-treatment differed in the range of doses that offered the
most potent protection. Co-treatment was more protective at the lower range of MitoQ
doses (0.05- 2.5 μM) and pre-treatment offered better overall protection among the higher
doses of MitoQ (1-5 μM). Overall, pre-treatment showed a more potent and higher
efficacy of protection than co-treatment.
In this study, we found that co-treatment started to show significantly lower levels
of DOX accumulation of at the lower doses of MitoQ (0.005-0.1 μM). By contrast, pretreatment demonstrated significant reductions among the higher doses of MitoQ (1-10
μM) accompanied with significantly higher reduction in DOX intracellular accumulation.
As suggested in the literature, MitoQ relies on Complex I and II to be recycled between
its oxidant and reduced form [40]. It is equally important to note that DOX depends on
complex I to transform to its reactive semiquinone form [12]. These interactions may
offer insight into why pre-treatment showed higher efficacy than co-treatment. Less
DOX accumulation would induce less superoxide production and less cell damage. In
consequence, we found that pre-treatment (1-10 μM) demonstrated significantly lower
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levels of superoxide accumulation than co-treatment. However, co-treatment (at the
MitoQ 10 µM dose) demonstrated a dose-dependent significant increase in both DOX
intracellular accumulation and superoxide anion levels (when compared to DOX 40 μM).
This coincides with the reduced level of cell viability demonstrated with co-treatment at
the same dose. MitoQ itself at higher dose (e.g., 10 μM) may become pro-oxidant and
potentiate DOX-induced oxidative stress.
Moreover, the reduced MMP also contributed to DOX accumulation in
mitochondrial after MitoQ was given as pre-treatment or co-treatment. We found that
cells treated with DOX with or without MitoQ had significant reduction of MMP when
compared to DOX alone. However, the degrees of MMP reduction were the similar as
MitoQ alone. Although MMP reduction can reduce ATP production, it may initiate some
protective mechanisms, such as activation of AMPK, mitophagy, and/or reduction of
superoxide production [12]. These affects can provide further protection against DOXinduced damage on the cellular level.
In addition to MitoQ’s antioxidant ability, Hu et al.’s study in 2018 indicated that
MitoQ pre-treatment activated Nrf2 signaling, which enhanced antioxidant capacity to
protect mitochondrial DNA in an intestinal ischemia/reperfusion model [42]. However,
the specific role Nrf2 has during cardioprotective needs to be further explored.
Our preliminary data found that MitoQ pre-treatment showed higher expression of
heme oxygenase 1 and superoxide dismutase 1, which might aid in quenching reactive
oxygen species. For example, heme oxygenase 1 transgenic mice models reveal that
overexpression of the antioxidant promoted a reduced infarct size following
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ischemia/reperfusion injury due to its overexpression and similar studies are discussed
regarding the antioxidant’s ability in providing protection against oxidative stress [24].
Similarly, superoxide dismutase 1 and related enzymes have been shown to control a
variety of ROS and reactive nitrogen species thus limiting the potential toxicity of these
molecules and offering protection against oxidative stress [26]. Our study demonstrated
that MitoQ, given as a pre-treatment, upregulated both antioxidant enzymes more than
co-treatment. This difference was also demonstrated when compared to DOX 40 µM.
Higher levels of antioxidant enzymes can better protect cells against oxidative stress [27].
However, more experiments need to be done to confirm this finding.

LIMITATION AND FUTURE STUDIES
We acknowledge that this study was performed on a rat H9c2 cardiomyoblast cell line
instead of primary cultured cardiomyocytes. However, the literature suggests that H9c2
cells and primary cardiomyocytes are very similar with regard to mitochondrial
biogenesis, function, and energy metabolism [42]. Additionally, we would like to validate
further the effects of pre-treatment of mitochondrial-targeted antioxidants in a Doxinduced cardiotoxicity animal model and collect more samples to demonstrate a clearer
Western Blot. Additionally, within the co-treatment and pre-treatment conditions, we
need to evaluate Mitoquinone’s protective effect against the anti-cancer properties of
DOX. In the literature, it has been demonstrated that MitoQ was 30 times more cytotoxic
to breast cancer cell lines than to healthy mammary epithelial cells [43]. It also increased
DOX’s anti-cancer effect while mitigating Dox-induced cardiotoxicity [43]. Finally,
given that MitoQ may compete with DOX to demonstrate its impact, it would be
interesting to see if pre-treatment or co-treatment would provide better anti-cancer
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effects. We also hope in our attempts to understand the relationship of MitoQ with DOX
that, we may provide insight on how patients can take antioxidants to prevent DOXinduced cardiotoxic effects.

CONCLUSION
In conclusion, DOX demonstrated a significant dose-dependent increase in mitochondrial
superoxide levels, a depolarization of the MMP, and an increase in its intracellular
accumulation, which promoted the dose-dependent decrease in cell viability for H9c2
cells. DOX alone may also reduce the expression of antioxidant enzymes, heme
oxygenase 1 and superoxide dismutase 1. Contrastingly, the present study demonstrated
that MitoQ alone did not significantly reduced cell viability. It was found to have
promoted a reduction in mitochondrial superoxide anion levels, and a reduction in MMP.
Though the latter is usually associated with cytotoxic effects, cell viability was not
significantly affected with respect to the depolarized MMP. Moreover, pre-treating H9c2
cells with MitoQ (1 uM- 10 uM) showed a higher reduction of DOX intracellular
accumulation and mitochondrial superoxide levels when compared to the co-treatment
condition. Additionally, pre-treatment also demonstrated an increased expression of heme
oxygenase 1 and superoxide dismutase 1, which may also promote more anti-oxidant
effects to protect cells against DOX-induced damage. Thus, MitoQ pre-treatment can
produce the best level of cardioprotection against the DOX induced damage. The
relationships demonstrated by our experiments can lead to the clinical applications of
providing patients with a preferred methods of treatment when supplementing DOX anticancer treatments with a mitochondrial antioxidant like MitoQ. For the future direction of
our studies, we hope to repeat western blots to develop clearer images and draw more
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conclusive statements regarding the expression of antioxidant enzymes. Finally, we
would like to explore if there is any interference with MitoQ and DOX in breast cancer
cells.
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